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A B S T R A C T
Purpose
The aim of the International Myeloma Working Group was to develop practice recommendations
for the management of multiple myeloma (MM) –related bone disease.
Methodology
An interdisciplinary panel of clinical experts on MM and myeloma bone disease developed
recommendations based on published data through August 2012. Expert consensus was used to
propose additional recommendations in situations where there were insufficient published data.
Levels of evidence and grades of recommendations were assigned and approved by panel members.
Recommendations
Bisphosphonates (BPs) should be considered in all patients with MM receiving first-line antimyeloma
therapy, regardless of presence of osteolytic bone lesions on conventional radiography. However, it is
unknown if BPs offer any advantage in patients with no bone disease assessed by magnetic resonance
imaging or positron emission tomography/computed tomography. Intravenous (IV) zoledronic acid
(ZOL) or pamidronate (PAM) is recommended for preventing skeletal-related events in patients with
MM. ZOL is preferred over oral clodronate in newly diagnosed patients with MM because of its
potential antimyeloma effects and survival benefits. BPs should be administered every 3 to 4 weeks
IV during initial therapy. ZOL or PAM should be continued in patients with active disease and should
be resumed after disease relapse, if discontinued in patients achieving complete or very good partial
response. BPs are well tolerated, but preventive strategies must be instituted to avoid renal toxicity or
osteonecrosis of the jaw. Kyphoplasty should be considered for symptomatic vertebral compression
fractures. Low-dose radiation therapy can be used for palliation of uncontrolled pain, impending
pathologic fracture, or spinal cord compression. Orthopedic consultation should be sought for
long-bone fractures, spinal cord compression, and vertebral column instability.
J Clin Oncol 31:2347-2357. © 2013 by American Society of Clinical Oncology
INTRODUCTION
Multiple myeloma (MM) is an incurable plasma-
cell malignancy,1,2 despite the improvement in sur-
vival after the introduction of novel agents.3,4 MM is
characterized by osteolytic bone disease resulting
from increased osteoclast activity and reduced os-
teoblast function.5-7 Osteolytic lesions are detected
in 70% to 80% of patients at diagnosis and increase
the risk for skeletal-related events (SREs; pathologic
fractures, spinal cord compression [SCC], require-
ment for surgery or palliative radiotherapy to
bone).8,9 SREs impair survival,10 undermine quality
of life (QoL),11 and increase treatment costs.12,13
Previous recommendations for the management of
MM with bisphosphonates (BPs) have been com-
piled by several organizations14-19 (Table 1), and the
International Myeloma Working Group (IMWG)
has also developed additional recommenda-
tions related to bone disease of MM and mono-
clonal gammopathy of undetermined significance
(MGUS).20-22 During the last years, several impor-
tant studies have been reported in the field. The
IMWG reviewed all available evidence; we provide
below recommendations for the management of
myeloma-related bone disease.
METHODOLOGY
An interdisciplinary panel of clinical experts on MM
and myeloma bone disease developed these recom-
mendations based on a review of evidence published
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in randomized clinical studies, meta-analyses, systematic reviews of
published clinical studies, observational studies, and case reports
through August 2012. Expert consensus was used to propose addi-
tional recommendations in situations where there were insufficient
published clinical data. Levels of evidence and grades of recommen-
dations were assigned using established criteria (Table 2). The recom-
mendations were initially circulated in draft form to each panel
member, who had an opportunity to comment on the levels of evi-
dence as well as the systematic grading of clinical data supporting each
recommendation. The manuscript subsequently underwent rounds
of revision until consensus was reached by all authors.
GUIDELINE RECOMMENDATIONS: BPS
PATIENT POPULATION AND CHOICE OF BP
Recommendations
BPs should be initiated in patients with MM, with (grade A) or
without (grade B) detectable osteolytic bone lesions on conventional
radiography, who are receiving antimyeloma therapy as well as pa-
tients with osteoporosis (grade A) or osteopenia (grade C) resulting
from myeloma. The beneficial effect of zoledronic acid (ZOL) in
patients without detectable bone disease by magnetic resonance im-
aging (MRI) or positron emission tomography/computed tomogra-
phy is not known.
Intravenous (IV) ZOL and pamidronate (PAM) exhibit compa-
rable efficacy in reducing SREs in patients with MM and are recom-
mended for preventing SREs in patients with active MM (grade A). IV
ZOL is recommended over oral clodronate (CLO) because it is signif-
icantly more efficacious in preventing SREs (grade A).
ZOL rather than CLO is recommended in patients with newly
diagnosed MM and bone disease at diagnosis because of its potential
antimyeloma effects and survival benefits (grade A). ZOL is the only
BP shown to increase survival in the whole studied population of a
prospective randomized trial. Clinical outcomes in patients with MM
who are not eligible for transplantation may also benefit from com-
bining ZOL with antimyeloma therapy (grade B).
BPs are recommended for those with low- and intermediate-risk
asymptomatic MM (AMM) if osteoporosis is identified by dual-
energy x-ray absorptiometry scan in doses used in patients with osteo-
porosis (grade C). For high-risk AMM, or if one cannot differentiate
between MM-related versus age-related bone loss, the treating physi-
cian should consider using dosing and schedule of BPs as with symp-
tomatic MM, especially in patients with abnormal MRIs (grade D;
panel consensus).
BPs are recommended for the treatment of osteoporosis in
MGUS in doses used for patients with osteoporosis (grade C). Dual-
energy x-ray absorptiometry scan should be considered for patients
with MGUS because of their reported increase in SREs compared with
age-matched controls (grade B).
For patients with a solitary lytic lesion and no evidence of osteo-
porosis, BP therapy is not indicated. If osteoporosis is present, BPs
should be administered as for osteoporosis patients. If multiple lesions
are present on MRI, the patient has MM bone disease and should be
treated with monthly IV BPs (grade C; panel consensus).
IV ZOL or PAM or oral CLO can be used to control bone pain
associated with myeloma bone disease (grade B). PAM 30 and 90 mg
have shown comparable effects for preventing SREs (grade B).
Evidence
Patients with symptomatic MM. Several studies have evaluated
the effects of BPs on SREs and bone pain in patients with MM (Table
3). Ibandronate is ineffective in reducing SREs or improving bone
pain in patients with MM.29 The oral BP, CLO, reduced the propor-
tion of patients with MM who experienced progression of osteolytic
lesions by 50% compared with placebo (24% v 12%; P .026)23 and
reduced the time to first nonvertebral fracture and the rate of nonver-
tebral fracture (6.8% v 13.2% for placebo; P  .04) in patients with
newly diagnosed MM.13 Administration of oral PAM failed to reduce
SREs relative to placebo.26 However, administration of IV PAM to
patients with myeloma with at least one osteolytic lesion resulted in a
significant reduction in SREs (24%) versus placebo (41%; P .001).
Patients receiving PAM also experienced reduced bone pain and no
deterioration in QoL during the 2-year study.27 A recent study in
patients with newly diagnosed MM (N  504) demonstrated that
PAM 30 mg monthly had comparable time to SREs and SRE-free
survival time compared with PAM 90 mg. Patients received PAM for
at least 3 years, and patients receiving PAM 30 mg showed a trend
Table 2. Levels of Evidence and Grades of Recommendations
Level/Grade Description
Level of evidence
I Evidence obtained from meta-analysis of multiple well-designed, controlled studies; randomized trials with low
false-positive and low false-negative errors (high power)
II Evidence obtained from at least one well-designed experimental study; randomized trials with high false-
positive and/or false-negative errors (low power)
III Evidence obtained from well-designed, quasi-experimental studies such as nonrandomized controlled single-
group, pre-post, cohort, time, or matched case-control series
IV Evidence from well-designed, nonexperimental studies such as comparative and correlational descriptive and
case studies
V Evidence from case reports and clinical examples
Grade of recommendation
A There is evidence of type I or consistent findings from multiple studies of types II, III, or IV
B There is evidence of types II, III, or IV, and findings are generally consistent
C There is evidence of types II, III, or IV, but findings are inconsistent
D There is little or no systematic empirical evidence
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toward lower risks of osteonecrosis of the jaw (ONJ) and nephrotox-
icity relative to PAM 90 mg.30 However, the study was not powered to
show SRE differences between the two PAM dosages but only to show
QoL differences.
ZOL was at least as effective as PAM in reducing the incidence of
SREs and pain and delaying the time to first SRE in patients with MM
in the conventional chemotherapy era.31-33 The recent Medical Re-
search Council Myeloma IX (MRC-IX) study (N  1,960) demon-
strated that a significantly smaller proportion of patients with newly
diagnosed MM receiving ZOL versus oral CLO in addition to first-line
antimyeloma therapy developed SREs before progression (27.0% v
35.3% for CLO; P .001).34,35 ZOL reduced the risk of SREs by 26%
relative to CLO (hazard ratio [HR], 0.74; P .001). Reduction in the
risk of any SRE was evident in ZOL-treated patients with (HR,
0.774; P .0038) and without (HR, 0.53; P .0068) bone lesions
at baseline over CLO-treated patients. This is the first time that a
BP showed a reduction in SREs in patients with myeloma who
required therapy and had no bone disease, assessed by conven-
tional radiography at baseline.35 Furthermore, ZOL significantly
reduced the risk of SREs versus CLO regardless of whether patients
received thalidomide maintenance.36
The MRC-IX study also demonstrated that addition of ZOL to
standard first-line antimyeloma therapy reduced the risk of death by
16% (P  .012) and prolonged median overall survival (OS) by 5.5
months (50 v 44.5 months) and median progression-free survival by 2
months (19.5 v 17.5 months) over CLO.34 In subset analyses, the OS
advantage with ZOL over CLO was observed only in patients with
bone disease at baseline (HR, 0.82; P .0107).36 However, it is impor-
tant to mention that the multiple unplanned subanalyses of the
MRC-IX study were a concern for several members of the group.
Other BPs have been also associated with improved survival in
subsets of patients. Patients receiving second-line antimyeloma
chemotherapy and treated with PAM experienced a borderline im-
provement in OS over placebo (Table 4),28 whereas CLO had an OS
advantage in patients without vertebral fractures at presentation rela-
tive to placebo.25 A recent meta-analysis showed that ZOL was the
only BP associated with superior OS compared with placebo (HR,
0.61; 95% CI, 0.28 to 0.98) but not compared with other BPs.37
Patients with AMM. IV PAM (60 to 90 mg monthly for 12
months) in patients with AMM reduced bone involvement at progres-
sion but did not decrease the risk or increase the time to progression.38
Similarly, IV ZOL (4 mg monthly for 12 months) reduced the SRE risk
at progression but did not influence the risk of progression in patients
with AMM.39
Several studies have reported the value of MRI (presence of 
one focal lesion and presence of diffuse pattern of marrow infiltration)
in detecting patients with AMM at high risk for progression.40,41
Because there are no data supporting progression-free survival advan-
tage with BPs in AMM, BPs should not be recommended except in a
clinical trial of high-risk patients.
Patients with MGUS. Patients with MGUS are at high risk for
developing osteoporosis and pathologic fractures.42,43 Three doses of
ZOL (4 mg IV every 6 months) increased bone mineral density (BMD)
by 15% in the lumbar spine and by 6% in the femoral neck in patients
with MGUS with osteopenia or osteoporosis.44 Oral alendronate (70
mg weekly) also increased BMD of the lumbar spine and total femur
by 6.1% and 1.5%, respectively, in 50 patients with MGUS with verte-
bral fractures and/or osteoporosis.45
Patients with solitary plasmacytoma. Patients with solitary plas-
macytoma and no evidence of MM do not require therapy with BPs.
Table 3. Large Controlled Studies of BP Therapy in Multiple Myeloma
Controlled Trial Year BP Dosage MM (No. of patients) Reduction of SREs Survival Benefit
Placebo
Lahtinen et al23 1992 CLO 2.4 g per day orally for 2 years 350 Yes NE
Laakso et al24 1994
McCloskey et al13 1998 CLO 1.6 g per day orally 530 Yes Subset†
McCloskey et al25 2001
Brincker et al26 1998 PAM 300 mg per day orally 300 No No
Berenson et al27 1996 PAM 90 mg IV every 4 weeks for 21 cycles 392 Yes Subset‡
Berenson et al28 1998
Menssen et al29 2002 IBN 2 mg IV once per month 198 No No
PAM, 90 mg
Gimsing et al30 2010 PAM 30 v 90 mg IV every 4 weeks 504 Comparable No change
Berenson et al31 2001 ZOL 2 or 4 mg IV once per month 108 Yes NE
Rosen et al32 2001 ZOL 4 or 8 mg IV once per month 513 Yes Subset§
Rosen et al33 2003
CLO, 1.6 g
Morgan et al34 2010 ZOL 4 mg IV every 3 to 4 weeks 1,960 Yes Yes
Morgan et al35 2011
Morgan et al36 2012
NOTE. Data adapted.19,30,34
Abbreviations: BP, bisphosphonate; CLO, clodronate; IBN, ibandronate; IV, intravenous; MM, multiple myeloma; NE, not evaluated; PAM, pamidronate; SRE,
skeletal-related event; ZOL, zoledronic acid.
SREs include vertebral and nonvertebral fractures, need for radiation or surgery to bone, spinal cord compression.
†In post hoc analysis, patients without vertebral fracture at study entry survived significantly longer with CLO (median survival, 23 months) compared with placebo.
‡Survival in patients with more advanced disease was significantly increased in the PAM group (median survival, 21 v 14 months; P  .041, adjusted for baseline
serum 2-microglobulin and Eastern Cooperative Oncology Group performance status).
§Survival benefit with ZOL over PAM in subgroup of patients who had elevated baseline bone-specific alkaline phosphatase levels.
Terpos et al
2350 © 2013 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Ta
bl
e
4.
C
lin
ic
al
O
ut
co
m
es
in
P
at
ie
nt
s
W
ith
M
ul
tip
le
M
ye
lo
m
a
Tr
ea
te
d
W
ith
B
is
ph
os
ph
on
at
e
Th
er
ap
y
S
tu
dy
Y
ea
r
P
at
ie
nt
P
op
ul
at
io
n
Tr
ea
tm
en
t
O
ve
ra
ll
S
ur
vi
va
l
P
ro
gr
es
si
on
-F
re
e
S
ur
vi
va
l
M
ed
ia
n
(m
on
th
s)
H
R
95
%
C
I
P
M
ed
ia
n
(m
on
th
s)
H
R
95
%
C
I
P
M
or
ga
n
et
al
(M
R
C
M
ye
lo
m
a
IX
)3
4
20
10
N
ew
ly
di
ag
no
se
d
pa
tie
nt
s
w
ith
M
M
ZO
L
(n

98
1)
50
0.
84
2
0.
74
to
0.
96
.0
12
19
.5
0.
88
3
0.
80
to
0.
98
.0
18
C
LO
(n

97
9)
44
.5
17
.5
B
er
en
so
n
et
al
2
8
19
98
P
at
ie
nt
s
w
ith
M
M
w
ho
re
ce
iv
ed
se
co
nd
-li
ne
an
tim
ye
lo
m
a
ch
em
ot
he
ra
py
(s
tr
at
um
tw
o)
P
A
M
(n

66
)
21
N
/A
.0
81
N
/A
N
/A
N
/A
P
LA
(n

65
)
14
M
cC
lo
sk
ey
et
al
2
5
20
01
P
at
ie
nt
s
w
ith
no
ve
rt
eb
ra
lf
ra
ct
ur
es
at
pr
es
en
ta
tio
n
C
LO
(n

73
)
59
0.
62
0.
43
to
0.
87
.0
04
N
/A
N
/A
N
/A
P
LA
(n

80
)
37
A
bb
re
vi
at
io
ns
:
C
LO
,
cl
od
ro
na
te
;
H
R
,
ha
za
rd
ra
tio
;
M
M
,
m
ul
tip
le
m
ye
lo
m
a;
M
R
C
,
M
ed
ic
al
R
es
ea
rc
h
C
ou
nc
il;
N
/A
,
no
t
ap
pl
ic
ab
le
;
P
A
M
,
pa
m
id
ro
na
te
;
P
LA
,
pl
ac
eb
o;
ZO
L,
zo
le
dr
on
ic
ac
id
.
Multiple Myeloma Bone Disease Treatment Recommendations
www.jco.org © 2013 by American Society of Clinical Oncology 2351
However, these patients should undergo whole body MRI, because in
a study of 17 patients diagnosed with a solitary plasmacytoma, all
showed additional focal lesions or diffuse infiltration on MRI, leading
to classification as stage I MM (76%), stage II MM (12%), or stage III
MM (12%) using the Durie-Salmon Plus system.46
ROUTE OF ADMINISTRATION
Recommendations
IV administration of BPs is the preferred choice (grade A). Home
IV infusion or oral administration may be considered for patients who
cannot receive hospital care (grade D).
Evidence
Strict adherence to dosing recommendations is required for BP
therapy to effectively reduce and delay SREs in patients with MM.
Each patient prescribed BP therapy should be instructed about the
crucial importance of adherence to the dosing regimen. Although a
few randomized, placebo-controlled clinical studies have suggested
that long-term compliance with oral BPs such as CLO is satisfactory in
patients with MM,13,23 compliance with oral BP therapy is generally
suboptimal.47 Furthermore, the MRC-IX data strongly support the
use of IV ZOL over CLO in all outcomes measured, including reduc-
tion of SREs and improvement in OS.34-36 However, oral administra-
tion remains an option for patients who cannot receive regular
hospital care or in-home nursing visits.
Administration of IV BPs such as ZOL or PAM is generally
performed as an outpatient procedure in a clinical environment but
may also be performed at home.48 Routine patient monitoring can be
combined with the administration of the IV infusion. Infusion times
range from 15 minutes for ZOL to 2 to 4 hours for PAM. One study
reported that 92% of patients preferred ZOL over PAM because of the
shorter infusion time.49
TREATMENT DURATION
Recommendations
IV BPs should be administered at 3- to 4-week intervals to all
patients with active MM (grade A). ZOL improves OS and reduces
SREs over CLO in patients who received treatment for more than 2
years; thus, it should be administered until disease progression in
patients not achieving complete response (CR) or very good partial
response (VGPR) and further continued at relapse (grade B). There is
not similar evidence for PAM. PAM may be continued in patients with
active disease at the physician’s discretion (grade D), and PAM ther-
apy should be resumed after disease relapse (grade D). For patients in
CR or VGPR, the optimal treatment duration of BPs is not clear; the
panel agrees that BPs should be administered for at least 12 months
and up to 24 months and then at the physician’s discretion (grade D;
panel consensus). Because of higher reported rates of ONJ with ex-
tended duration of therapy, discontinuation of ZOL or PAM may be
considered after 1 to 2 years in patients who have achieved CR or
VGPR (grade D; panel consensus).
Evidence
Until data from the Bismarck and other trials using bone resorp-
tion markers to dictate dosing frequency are available, IV BPs should
be administered every 3 to 4 weeks, as per previous guidelines.15,19 The
subanalyses of the MRC-IX study showed that among patients who
received at least 2 years of BP therapy (n  582), ZOL reduced the
incidence of SREs versus CLO (log-rank P  .0102). More impor-
tantly, in the same group of patients, ZOL improved OS from initial
random assignment (median not reached; HR, 0.60; P .02) and after
first disease progression event versus CLO (34 v 27 months, respec-
tively; HR, 0.58; P .03).36 The panel supports the use of ZOL beyond
2 years and until disease progression for patients not in CR or VGPR,
because there are no data for survival or SRE advantage among pa-
tients achieving CR or VGPR. Indeed, the continuation of BPs in these
patients is an important issue, because novel agent–based therapies
have increased the CR/VGPR rate. A French study showed that PAM
alone as a maintenance therapy did not reduce SREs and had no
survival benefit compared with thalidomide alone in patients under-
going autologous stem-cell transplantation after a median time of 29
months.50 The CR/VGPR rate in this study was more than 55% in all
treatment arms. However, none of these patients received PAM before
its use as maintenance.50 Another small retrospective study in 44
patients with myeloma who were in sustained remission after antimy-
eloma therapy for more than 2 years showed an increase in lumbar
spine BMD progressively after a mean follow-up of 3 years; these
patients did not receive BPs, and thus, the BMD increase was related to
the sustained response to antimyeloma treatment.51 For these reasons,
BP therapy has been tested at a reduced dose or longer intervals,30,52
without the drawing of final conclusions because of limitations of
these studies.
ADVERSE EVENTS
Recommendations
Clinicians should ask their patients about symptoms suggesting
adverse events (AEs) and should monitor their patients for the devel-
opment of more serious complications. Patients should also be in-
structed on how to recognize AEs and on the importance of early
reporting (panel consensus).
Calcium and vitamin D3 supplementation should be used to
maintain calcium homeostasis (grade A). Calcium supplementation
should be used with caution in patients with renal insufficiency. All
BP-treated patients should have creatinine clearance (CrCl), serum
electrolytes, and urinary albumin monitored (grade A).
Preventive strategies should be adopted to avoid ONJ. Patients
should receive a comprehensive dental examination and be educated
regarding optimal dental hygiene (grade C; panel consensus). Existing
dental conditions should be treated before initiating BP therapy (grade
C; panel consensus).
After BP treatment initiation, unnecessary invasive dental proce-
dures should be avoided, and dental health status should be moni-
tored on at least an annual basis (grade C). Patients’ ongoing dental
health status should be monitored by a physician and dentist (grade D;
panel consensus). Dental problems should be managed conserva-
tively, if possible (grade C). Temporary suspension of BP treatment
should be considered if invasive dental procedures are necessary
(grade D). The panel consensus is to stop BPs for 90 days before and
after invasive dental procedures (eg, tooth extraction, dental implants,
and surgery to the jaw). BPs do not need to be discontinued for routine
dental procedures, including root canals.
Initial treatment of ONJ should include discontinuation of BPs
until healing occurs (grade C). The decision to restart BPs should be
Terpos et al
2352 © 2013 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
made on an individual basis until the results of prospective long-term
studies are available (grade D). The physician should consider the
advantages and disadvantages of continued treatment with BPs, espe-
cially in the relapsed/refractory MM setting (grade D).
Evidence
BP therapy is generally well tolerated in patients with MM. Po-
tential AEs associated with BP administration include hypocalcemia
and hypophosphatemia, GI events after oral administration, inflam-
matory reactions at the injection site, and acute-phase reactions after
IV administration of amino BPs. Renal impairment and ONJ repre-
sent infrequent but potentially serious AEs with BP use.
Hypocalcemia is usually relatively mild and asymptomatic with
BP use in most patients with MM. The incidence of symptomatic
hypocalcemia is much lower in those with MM compared with pa-
tients with solid tumors. Although severe hypocalcemia has been
observed in some patients,53 these events are usually preventable via
the administration of oral calcium and vitamin D3. Patients should
routinely receive calcium (600 mg per day) and vitamin D3 (400 IU
per day) supplementation; 60% of patients with MM are vitamin D
deficient or insufficient.54,55 Because vitamin D deficiency increases
bone remodeling, particularly parathyroid hormone levels, it is im-
portant that patients be calcium and vitamin D sufficient.56 Calcium
supplementation should be used with caution in patients with re-
nal insufficiency.
BP infusions are associated with both dose- and infusion rate–
dependent effects on renal function. The potential for renal damage is
generally dependent on the concentration of BP in the bloodstream,
and the highest risk is observed after administration of high dosages or
rapid infusion. Both ZOL and PAM have been associated with acute
renal damage or increases in serum creatinine.27,32-34,36,57-60 Patients
should be closely monitored for compromised renal function by mea-
suring CrCl before administration of each IV BP infusion. Patients
with mild to moderate renal impairment, defined by a CrCl rate of 30
to 60 mL/min, should receive reduced doses of CLO and ZOL under
close clinical monitoring, as previously recommended.19 No
change to ZOL infusion time is recommended. PAM should be
administered via extended infusion duration ( 4 hours), and
clinicians should also consider reducing the initial dose in patients
with renal impairment. PAM and ZOL are not recommended for
patients with CrCl 30 mL/min.
Early diagnosis is crucial, and urinary albumin and serum elec-
trolytes in addition to CrCl rates should be monitored in these pa-
tients. Oral CLO is contraindicated if CrCl is  12 mL/min.
Adherence to recommended infusion protocols regarding dosage,
infusion time, serum creatinine levels, and hydration is mandatory to
minimize the potential for renal damage. BP therapy should be dis-
continued in patients experiencing renal problems until serum creat-
inine levels return to within 10% of baseline values.
ONJ, characterized by exposed bone in the mouth that does not
heal with 6 to 8 weeks of therapy, is a potentially serious complication
of BP therapy. Retrospective studies have suggested that 4% and 11%
of patients develop ONJ.61,62 ZOL has been associated with a higher
reported rate of ONJ than other BPs, and the cumulative dose and
duration of therapy are believed to contribute to the development of
ONJ.61,62 In the MRC-IX study, the ONJ incidence with ZOL was
approximately 1% per year (5% at a median follow-up of 4.8 years);
these patients did not receive mandatory dental prophylaxis as part of
this trial.34,36 Among patients who received ZOL beyond 2 years, 4.1%
developed ONJ.36 In another prospective study comparing ZOL with
denosumab in patients with solid tumors and bone metastases or with
MM (10% of the population studied), the incidence of ONJ after 2
years was 1.3% with ZOL and 1.1% with denosumab.59 Additional
risk factors for ONJ include dental procedures, local infections, and
treatment with corticosteroids.61-63 The implementation of appropri-
ate preventive measures greatly reduced the number of ONJ cases.64-66
Clinical studies support restarting BP therapy after healing of ONJ. A
long-term follow-up study of 97 patients with MM with ONJ demon-
strated that patients who developed ONJ after dental procedures were
less likely to have recurrence or nonhealing lesions after BP reinitiation
upon healing of ONJ compared with patients who developed sponta-
neous ONJ.63 Recurrence of ONJ was linked to rechallenge with BP
therapy, mainly in the relapsed setting.63
KYPHOPLASTY AND VERTEBROPLASTY
Recommendations
Balloon kyphoplasty (BKP) should be considered for symptom-
atic vertebral compression fractures (VCFs) and is the procedure of
choice to improve QoL in patients with painful VCFs (grade A). The
role of vertebroplasty for patients with myeloma is less clear, be-
cause there are no randomized trials of vertebroplasty among
patients with myeloma.
Evidence
Several studies have demonstrated that BKP and vertebro-
plasty are well-tolerated and effective procedures that provide pain
relief and improve functional outcomes in patients with painful
neoplastic spinal fractures. A single randomized study of 134 pa-
tients with bone metastases resulting from solid tumors and MM
demonstrated that treatment of VCFs with BKP was associated
with clinically meaningful improvements in physical functioning,
back pain, QoL, and ability to perform daily activities relative to
nonsurgical management. These benefits persisted throughout the
12-month study.67 A meta-analysis of seven nonrandomized stud-
ies of patients with MM or osteolytic metastasis revealed that BKP
was associated with reduced pain and improved functional out-
comes, benefits that were maintained up to 2 years postprocedure
(N  306). BKP also improved early vertebral height loss and
spinal deformity, but these effects were not long term68 (Table 5).
Similarly, a retrospective review of 67 patients with MM-related
VCFs demonstrated that vertebroplasty provided clinically mean-
ingful improvements in physical functioning, pain, and mobility
throughout 12 months of follow-up.75 Several small nonrandom-
ized studies of BKP or BKP and vertebroplasty have generated
comparable results.76-78 However, the role of vertebroplasty for
patients with myeloma remains debatable in the absence of
prospective data,77,79 because two randomized trials failed to show
any benefit with vertebroplasty in patients with osteoporotic frac-
tures versus conservative therapy.80,81 Furthermore, a meta-
analysis of 59 studies (56-case series) showed that BKP seemed to
be more effective than vertebroplasty in relieving pain secondary to
cancer-related VCFs and was associated with lower rates of ce-
ment leakage.82
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RADIATION THERAPY
Recommendations
Low-dose radiation therapy (up to 30 Gy) can be used as pallia-
tive treatment for uncontrolled pain, impending pathologic fracture,
or impending SCC. Upfront external beam radiation therapy should
be considered for patients with plasmacytoma, extramedullary
masses, and SCC (grade C). However, the use of radiotherapy for local
disease control and palliation should be used judiciously and sparingly
depending on patient’s presentation, need for urgent response, and
treatment history and prior response. It should be limited as much as
possible to spare the patient’s marrow function. Current novel agents
work rapidly and should decrease the need for palliative radiotherapy.
Evidence
Several studies, a majority of which were retrospective and in-
cluded relatively small patient cohorts, have demonstrated that radio-
therapy provided pain relief, decreased analgesic use, promoted
recalcification, reduced neurologic symptoms, and improved motor
function and QoL in patients with MM.83-85 In addition, the total
administered dose should be limited and the field of therapy restricted,
especially when the aim of treatment is pain relief rather than treat-
ment or prevention of pathologic fractures. A single 8- to 10-Gy
fraction is generally recommended. Indeed, single fractions are in-
creasingly preferred to fractionated treatment. No difference in rapid-
ity of onset or duration of pain relief was observed between a single
8-Gy fraction and a fractionated 2-week course of 30 Gy in a random-
ized study of 288 patients with widespread bony metastases, including
23 patients with MM.86
MM accounts for 11% of the most-prevalent cancer diagnoses
causing SCC.87 In the largest retrospective series to date, radiotherapy
alone improved motor function in 75% of patients with MM and SCC.
One-year local control was 100%, and one-year survival was 94%.88
SURGERY
Recommendations
Orthopedic consultation should be sought for impending or
actual long-bone fractures, bony compression of the spinal cord, or
vertebral column instability (grade D). Consideration and indications
for surgery should occur in consultation with the treating oncologist/
hematologist and the orthopedic and neurosurgeon to determine
when MM treatment can be safely restarted.
Evidence
Surgery is usually directed toward preventing or repairing axial
fractures, unstable spinal fractures, and SCC in patients with myelo-
ma. Decompression laminectomy is rarely required in those with
Table 5. Efficacy of Balloon Kyphoplasty for Malignant Spinal Fractures: Results of a Meta-Analysis
Variable
No. of
Studies
No. of Patients
or Levels Size of Effect 95% CI P I2 (%)
Pain: VAS score (0-10)
Basal (postoperative) 469-72 172 patients SMD: 3.85 2.99 to 4.71  .001 79
Baseline (end of follow-up) 370-72 109 patients SMD: 4.27 2.38 to 6.21  .001 93
Functional capacity: ODI (0-100)
Baseline (postoperative) 469,71,72 173 patients WMD: 28.78 11.5 to 46.0 .001 99
Baseline ( 6 months) 269,73 82 patients WMD: 16.39 14.25 to 18.5 .001 0
Baseline (2 years) 271,72 91 patients WMD: 41.95 39.42 to 44.5 .001 0
Kyphotic deformity: Cobb angle
Basal (postoperative) 371,72,74 180 levels SMD: 0.69 0.20 to 1.16 .001 78
Baseline (end of follow-up) 371,72,74 155 levels SMD: 0.39 0.05 to 0.84 .08 74
Vertebral height 369,70,74 342 levels RR: 47% 33% to 61% 38
Percentage of restitution
increase, mm
271,72 158 levels
Anterior vertebral body
Basal (postoperative) SMD: 0.28 0.06 to 0.51 .01 0
Baseline (end of follow-up) SMD: 0.15 0.16 to 0.45 .35 37
Midline vertebral body
Basal (postoperative) SMD: 0.28 0.003 to 0.56 .04 34
Baseline (end of follow-up) SMD: 0.15 0.17 to 0.46 .35 41
NOTE. All based on random effects meta-analysis. Reprinted with permission.68
Abbreviations: ODI, Oswestry Disability Index; RR, rate ratio; SMD, standardized mean difference; VAS, visual analogue scale; WMD, weighted mean difference.
Table 6. New Recommendations for Use of Bisphosphonates in
Multiple Myeloma
Factor Recommendation
Patient population Newly diagnosed patients with MM who require
antimyeloma treatment (regardless of bone status)
Administration IV
Duration/frequency Monthly during initial therapy and ongoing in patients
who are not in remission
After 2 years, discontinue if CR/VGPR; continue if
 PR
Monitoring Monthly creatinine clearance
Choice ZOL (first option)
PAM (second option)
CLO (only in patients who cannot come to hospital,
those with severe disabilities, and those with
contraindications to ZOL and PAM)
Abbreviations: CLO, clodronate; CR, complete response; IV, intravenous; MM,
multiple myeloma; PAM, pamidronate; PR, partial response; VGPR, very good
partial response; ZOL, zoledronic acid.
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MM, but radioresistant MM or retropulsed bone fragments may re-
quire surgical intervention.89 In a relatively large study, 75 patients
with MM were treated surgically (83 interventions) for skeletal com-
plications of the disease. Most of the lesions were in the axial skeleton
or the proximal extremities, apart from one distal lesion of the fibula,
and most surgery was performed in the spine (35 patients). Surgical
treatment in these patients was mostly limited to a palliative approach
and was well tolerated.90
DISCUSSION
BPs are recommended in all patients with MM requiring front-line
therapy, regardless of the presence of bone disease at diagnosis, as-
sessed by conventional radiography. Although ZOL, PAM, and CLO
reduce SREs and control bone pain compared with placebo, ZOL is
associated with improved survival in patients with newly diagnosed
MM and bone disease and reduces SREs over CLO. This benefit
remains in patients who receive ZOL for more than 2 years. Therefore,
ZOL should be administered until disease progression, except in pa-
tients who have achieved CR or VGPR, for whom there are no data
regarding the survival advantage of ZOL. For PAM, there are no data
demonstrating a survival advantage; it can be administered up to 2
years and continued at the physician’s discretion in a patient with
active myeloma. BP therapy is generally well tolerated, but preventive
strategies should be adopted to avoid renal impairment or ONJ. Local
radiotherapy should be considered for painful bone lesions and BKP
for the treatment of VCFs (Table 6).
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